Expamers: a New Technology to Control T Cell Activation

Overview

Journal Sci Rep

Specialty Science

Date 2020 Oct 21

PMID 33082362

Citations 13

Authors

Mateusz P Poltorak

Patricia Graef

Claudia Tschulik

Michaela Wagner

Vlad Cletiu

Stefan Dreher

Bojana Borjan

Simon P Fraessle

Manuel Effenberger

Martin Turk

Dirk H Busch

Juergen Plitzko

David G Kugler

Seamus Ragan

Thomas Schmidt

Christian Stemberger

Lothar Germeroth

Affiliations

Soon will be listed here.

Abstract

T cell activation is a cornerstone in manufacturing of T cell-based therapies, and precise control over T cell activation is important in the development of the next generation T-cell based therapeutics. This need cannot be fulfilled by currently available methods for T cell stimulation, in particular not in a time dependent manner. Here, we describe a modular activation reagent called Expamers, which addresses these limitations. Expamers are versatile stimuli that are intended for research and clinical use. They are readily soluble and can be rapidly bound and removed from the cell surface, allowing nearly instantaneous initiation and termination of activation signal, respectively. Hence, Expamers enable precise regulation of T cell stimulation duration and provide promise of control over T cell profiles in future products. Expamers can be easily adopted to different T cell production formats and have the potential to increase efficacy of T cell immunotherapeutics.

Citing Articles

Emerging approaches for T cell-stimulating platform development.

Ariail E, Garcia Espinoza N, Stephenson A, Spangler J Cell Syst. 2024; 15(12):1198-1208.

PMID: 39701036 PMC: 11665896. DOI: 10.1016/j.cels.2024.11.007.

Optimizing CAR-T treatment: A TEVOLVE guide to raw and starting material selection.

Navarro S, Moukheiber C, Inoges Sancho S, Ruiz Guillen M, Lopez-Diaz de Cerio A, Sanges C Mol Ther. 2024; 33(3):847-865.

PMID: 39533710 PMC: 11897765. DOI: 10.1016/j.ymthe.2024.11.017.

CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects.

Choudhery M, Arif T, Mahmood R, Harris D J Clin Med. 2024; 13(11).

PMID: 38892913 PMC: 11172642. DOI: 10.3390/jcm13113202.

Separation of Activated T Cells Using Multidimensional Double Spiral (MDDS) Inertial Microfluidics for High-Efficiency CAR T Cell Manufacturing.

Jeon H, Perez C, Kyung T, Birnbaum M, Han J Anal Chem. 2024; 96(26):10780-10790.

PMID: 38889002 PMC: 11818483. DOI: 10.1021/acs.analchem.4c01981.

T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function.

Underwood S, Jin J, Shao L, Prochazkova M, Shi R, Song H Immunohorizons. 2024; 8(6):404-414.

PMID: 38864817 PMC: 11220740. DOI: 10.4049/immunohorizons.2400008.

References

Schober K, Muller T, Gokmen F, Grassmann S, Effenberger M, Poltorak M . Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019; 3(12):974-984. DOI: 10.1038/s41551-019-0409-0. View

Turtle C, Riddell S . Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol. 2011; 23(2):299-305. PMC: 3130496. DOI: 10.1016/j.coi.2010.12.012. View

Davis S, Anton van der Merwe P . The kinetic-segregation model: TCR triggering and beyond. Nat Immunol. 2006; 7(8):803-9. DOI: 10.1038/ni1369. View

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M . Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 2017; 31(10):2161-2171. DOI: 10.1038/leu.2017.16. View

Berg N, Puente L, Dawicki W, Ostergaard H . Sustained TCR signaling is required for mitogen-activated protein kinase activation and degranulation by cytotoxic T lymphocytes. J Immunol. 1998; 161(6):2919-24. View

Vormittag P, Gunn R, Ghorashian S, Veraitch F . A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018; 53:164-181. DOI: 10.1016/j.copbio.2018.01.025. View

Mehlhop-Williams E, Bevan M . Memory CD8+ T cells exhibit increased antigen threshold requirements for recall proliferation. J Exp Med. 2014; 211(2):345-56. PMC: 3920562. DOI: 10.1084/jem.20131271. View

Pozarowski P, Darzynkiewicz Z . Analysis of cell cycle by flow cytometry. Methods Mol Biol. 2004; 281:301-11. DOI: 10.1385/1-59259-811-0:301. View

Van Stipdonk M, Lemmens E, Schoenberger S . Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol. 2001; 2(5):423-9. DOI: 10.1038/87730. View

10.

Voss S, Skerra A . Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng. 1997; 10(8):975-82. DOI: 10.1093/protein/10.8.975. View

11.

Wang X, Simeoni L, Lindquist J, Saez-Rodriguez J, Ambach A, Gilles E . Dynamics of proximal signaling events after TCR/CD8-mediated induction of proliferation or apoptosis in mature CD8+ T cells. J Immunol. 2008; 180(10):6703-12. DOI: 10.4049/jimmunol.180.10.6703. View

12.

Boerman O, van Schaijk F, Oyen W, Corstens F . Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003; 44(3):400-11. View

13.

Ghassemi S, Nunez-Cruz S, OConnor R, Fraietta J, Patel P, Scholler J . Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunol Res. 2018; 6(9):1100-1109. PMC: 8274631. DOI: 10.1158/2326-6066.CIR-17-0405. View

14.

Meyer R, Sunshine J, Perica K, Kosmides A, Aje K, Schneck J . Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small. 2015; 11(13):1519-25. PMC: 4529071. DOI: 10.1002/smll.201402369. View

15.

Riddell S, Greenberg P . The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990; 128(2):189-201. DOI: 10.1016/0022-1759(90)90210-m. View

16.

Rossy J, Williamson D, Gaus K . How does the kinase Lck phosphorylate the T cell receptor? Spatial organization as a regulatory mechanism. Front Immunol. 2012; 3:167. PMC: 3377954. DOI: 10.3389/fimmu.2012.00167. View

17.

Liu J, Zhou G, Zhang L, Zhao Q . Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. Front Immunol. 2019; 10:456. PMC: 6433930. DOI: 10.3389/fimmu.2019.00456. View

18.

Srivastava S, Salter A, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K . Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019; 35(3):489-503.e8. PMC: 6450658. DOI: 10.1016/j.ccell.2019.02.003. View

19.

Choudhuri K, Dustin M . Signaling microdomains in T cells. FEBS Lett. 2010; 584(24):4823-31. PMC: 3870024. DOI: 10.1016/j.febslet.2010.10.015. View

20.

Daniels M, Teixeiro E, Gill J, Hausmann B, Roubaty D, Holmberg K . Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature. 2006; 444(7120):724-9. DOI: 10.1038/nature05269. View